Terms: = Bone cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
15 results:
1. Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis.
Camilli S; Lockey R; Kolliputi N
Cell Biochem Biophys; 2023 Sep; 81(3):421-426. PubMed ID: 37126200
[TBL] [Abstract] [Full Text] [Related]
2. Selinexor decreases HIF-1α via inhibition of crm1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract] [Full Text] [Related]
3. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
[TBL] [Abstract] [Full Text] [Related]
4. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
Theodoropoulos N; Lancman G; Chari A
Target Oncol; 2020 Dec; 15(6):697-708. PubMed ID: 33074469
[TBL] [Abstract] [Full Text] [Related]
5. p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma.
Currier AW; Kolb EA; Gorlick RG; Roth ME; Gopalakrishnan V; Sampson VB
Sci Rep; 2019 Apr; 9(1):6161. PubMed ID: 30992462
[TBL] [Abstract] [Full Text] [Related]
6. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
Hu B; Patel KP; Chen HC; Wang X; Wang F; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating MJ; Wierda WG
Br J Haematol; 2019 Jun; 185(5):852-864. PubMed ID: 30924136
[TBL] [Abstract] [Full Text] [Related]
7. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract] [Full Text] [Related]
8. treatment of acquired drug resistance in multiple myeloma by combination therapy with xpo1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract] [Full Text] [Related]
9. crm1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
[TBL] [Abstract] [Full Text] [Related]
10. Novel reversible selective inhibitor of nuclear export shows that crm1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract] [Full Text] [Related]
11. xpo1/crm1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract] [Full Text] [Related]
12. crm1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
Tai YT; Landesman Y; Acharya C; Calle Y; Zhong MY; Cea M; Tannenbaum D; Cagnetta A; Reagan M; Munshi AA; Senapedis W; Saint-Martin JR; Kashyap T; Shacham S; Kauffman M; Gu Y; Wu L; Ghobrial I; Zhan F; Kung AL; Schey SA; Richardson P; Munshi NC; Anderson KC
Leukemia; 2014 Jan; 28(1):155-65. PubMed ID: 23588715
[TBL] [Abstract] [Full Text] [Related]
13. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by crm1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
Falini B; Martelli MP; Bolli N; Bonasso R; Ghia E; Pallotta MT; Diverio D; Nicoletti I; Pacini R; Tabarrini A; Galletti BV; Mannucci R; Roti G; Rosati R; Specchia G; Liso A; Tiacci E; Alcalay M; Luzi L; Volorio S; Bernard L; Guarini A; Amadori S; Mandelli F; Pane F; Lo-Coco F; Saglio G; Pelicci PG; Martelli MF; Mecucci C
Blood; 2006 Sep; 108(6):1999-2005. PubMed ID: 16720834
[TBL] [Abstract] [Full Text] [Related]
15. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
Nunez SB; Calis K; Cutler GB; Jones J; Feuillan PP
J Clin Endocrinol Metab; 2003 Dec; 88(12):5730-3. PubMed ID: 14671160
[TBL] [Abstract] [Full Text] [Related]
